Jianzhao Zhang

Prof. Jianzhao Zhang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2019 in Oncology Letters
Verified
Journal Article
Open access
PDF file
BHBing Han
Bing Han
HWHongbo Wang
Hongbo Wang
JZJianzhao Zhang
Jianzhao Zhang
JTJingwei Tian
Jingwei Tian
Currently, the occurrence and mortality rate of cervical cancer is high, particularly in low‑to‑middle‑income countries. Therefore, the development of novel diagnostic and treatment strategies for cervical cancer is urgently required. The aim of the present study was to assess the prognostic significance of fibronectin type III domain containing 3B (FNDC3B) expression in patients with cervical cancer and to determine the underlying mechanism of FNDC3 in tumor development. Analysis of the ONCOMINE database revealed that FNDC3B was significantly upregulated in cervical cancer tissue compared with normal tissue. Additionally, FNDC3B expression data and the clinical characteristics of patients with cervical cancer were obtained from the cBioPortal database. Correlations between FNDC3B expression and overall survival were subsequently investigated. The results revealed that increased FNDC3B expression was significantly correlated with a lower overall survival in patients with cervical cancer. A co‑expression network was subsequently constructed to elucidate the function of FNDC3B in cervical cancer. Co‑expression genes for FNDC3B were obtained from the cBioPortal database and were subjected to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses. The results demonstrated that the genes were enriched in pathways associated with migration, invasion, endoplasmic reticulum (ER) stress and the unfolded protein response (UPR). Furthermore, immunofluorescence results obtained from the Human Protein Atlas revealed that the FNDC3B protein was localized to the ER. The results revealed that upregulated FNDC3B expression may be a biomarker for poor prognosis for patients with cervical cancer. Additionally, the results revealed that FNDC3B may serve an oncogenic role in cancer development via ER stress, UPR, cell migration and invasion. However, further studies are required to determine the exact molecular mechanism of FNDC3B in the development of cervical cancer and to assess its potential as a novel therapeutic target for the treatment of this disease.

13 September 2024 in Molecules
Verified
Journal Article
Open access
PDF file
RMRunchen Ma
Runchen Ma
SXSun Xiaohui
Sun Xiaohui
ZLZhaofeng Liu
Zhaofeng Liu
JZJianzhao Zhang
Jianzhao Zhang
GYGangqiang Yang
Gangqiang Yang
WYWang Yunjie
Wang Yunjie
Stroke is a severe neurological disorder resulting from the rupture or blockage of blood vessels, leading to significant mortality and disability worldwide. Among the different types of stroke, ischemic stroke (IS) is the most prevalent, accounting for 70–80% of cases. Cell death following IS occurs through various mechanisms, including apoptosis, necrosis, and ferroptosis. Ferroptosis, a recently identified form of regulated cell death characterized by iron overload and lipid peroxidation, was first described by Dixon in 2012. Currently, the only approved pharmacological treatment for IS is recombinant tissue plasminogen activator (rt-PA), which is limited by a narrow therapeutic window and often results in suboptimal outcomes. Recent research has identified several traditional Chinese medicines (TCMs) that can inhibit ferroptosis, thereby mitigating the damage caused by IS. This review provides an overview of stroke, the role of ferroptosis in IS, and the potential of certain TCMs to inhibit ferroptosis and contribute to stroke treatment.

4 February 2024 in Molecules
Verified
Journal Article
Open access
PDF file
ZLZhaofeng Liu
Zhaofeng Liu
YYYifei Yang
Yifei Yang
SXSun Xiaohui
Sun Xiaohui
RMRunchen Ma
Runchen Ma
WZWenjing Zhang
Wenjing Zhang
JTJingwei Tian
Jingwei Tian
Cell cycle-dependent kinase 2 (CDK2) is located downstream of CDK4/6 in the cell cycle and regulates cell entry into S-phase by binding to Cyclin E and hyper-phosphorylating Rb. Proto-oncogene murine double minute 2 (MDM2) is a key negative regulator of p53, which is highly expressed in tumors and plays an important role in tumorigenesis and progression. In this study, we identified a dual inhibitor of CDK2 and MDM2, III-13, which had good selectivity for inhibiting CDK2 activity and significantly reduced MDM2 expression. In vitro results showed that III-13 inhibited proliferation of a wide range of tumor cells, regardless of whether Cyclin E1 (CCNE1) was overexpressed or not. The results of in vivo experiments showed that III-13 significantly inhibited proliferation of tumor cells and did not affect body weight of mice. The results of the druggability evaluation showed that III-13 was characterized by low bioavailability and poor membrane permeability when orally administered, suggesting the necessity of further structural modifications. Therefore, this study provided a lead compound for antitumor drugs, especially those against CCNE1-amplified tumor proliferation.

17 August 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FZFangxia Zou
Fangxia Zou
YWYao Wang
Yao Wang
DYDawei Yu
Dawei Yu
CLChunjiao Liu
Chunjiao Liu
JLJing Lu
Jing Lu
JTJingwei Tian
Jingwei Tian

19 June 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZSZiwei Song
Ziwei Song
LYLiang Ye
Liang Ye
YWYunjie Wang
Yunjie Wang
WWWenyan Wang
Wenyan Wang
CLChunjiao Liu
Chunjiao Liu
JTJingwei Tian
Jingwei Tian

21 April 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YWYunjie Wang
Yunjie Wang
ZLZhaofeng Liu
Zhaofeng Liu
JLJing Lu
Jing Lu
WWWenyan Wang
Wenyan Wang
LWLin Wang
Lin Wang
JTJingwei Tian
Jingwei Tian
Introduction: Schizophrenia is a serious mental illness that requires effective treatment with minimal adverse effects. As preclinical and clinical research progresses, trace amine-associated receptor 1 (TAAR1) is becoming a potential new target for the treatment of schizophrenia.Methods: We used molecular docking and molecular dynamics (MD) simulations to discover TAAR1 agonists. The agonistic or inhibitory effects of compounds on TAAR1, 5-HT1A, 5-HT2A, and dopamine D2-like receptors were determined. We used an MK801-induced schizophrenia-like behavior model to assess the potential antipsychotic effects of compounds. We also performed a catalepsy assay to detect the adverse effects. To evaluate the druggability of the compounds, we conducted evaluations of permeability and transporter substrates, liver microsomal stability in vitro, human ether-à-go-go-related gene (hERG), pharmacokinetics, and tissue distribution.Results: We discovered two TAAR1 agonists: compounds 50A and 50B. The latter had high TAAR1 agonistic activity but no agonistic effect on dopamine D2-like receptors and demonstrated superior inhibition of MK801-induced schizophrenia-like behavior in mice. Interestingly, 50B had favorable druggability and the ability to penetrate the blood-brain barrier (BBB) without causing extrapyramidal symptoms (EPS), such as catalepsy in mice.Conclusion: These results demonstrate the potential beneficial role of TAAR1 agonists in the treatment of schizophrenia. The discovery of a structurally novel TAAR1 agonist (50B) may provide valuable assistance in the development of new treatments for schizophrenia.